Tetra Bio-Pharma (OTCQB:TBPMF; CSE:TBP) has signed a letter of intent with Constance Therapeutics of San Francisco for the clinical development and commercialization in Canada of its signature medicinal cannabis extract products.
In a statement, Constance Finley, founder and CEO of Constance Therapeutics, said the company works in conjunction with physicians and medical professionals to provide integrative medicinal options to those suffering from serious conditions, such as cancer, lyme, auto-immune, chronic pain, neurodegenerative diseases and other out-of-option patients.
"Over the years, research demonstrates that cannabinoids, including specific terpenes, reduce and inhibit tumor growth in various animal models,” she added. “Early clinical studies suggest cannabinoids enhance the effects of traditional cancer treatments with radiation therapy and help reduce the size of brain cancers, such as glioma, compared to controls."
Tetra will enter into a licensing agreement with Constance Therapeutics to perform clinical research on the novel cannabis extract products, initially focusing on their use in treating patients with brain cancer. These products are currently available to patients living in California and are consumed sublingually and through vaporization.